feed,title,long_url,short_url
Benzinga,Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD),https://www.benzinga.com/pressreleases/20/07/g16509306/inventiva-announces-the-decision-by-the-investigator-to-reduce-the-number-of-patients-in-the-ongoi,https://j.mp/2BG9oFW
Benzinga,Approval of the Draft Safeguard Plan by the Creditors' Committee,https://www.benzinga.com/pressreleases/20/07/g16509305/approval-of-the-draft-safeguard-plan-by-the-creditors-committee,https://j.mp/3f6msTE
